Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een studie van Ustekinumab bij pediatrische deelnemers met matig tot ernstig actieve ziekte van Crohn (UNITI Jr)

2 juli 2026 bijgewerkt door: Janssen Research & Development, LLC

Een fase 3-onderzoek naar de werkzaamheid, veiligheid en farmacokinetiek van Ustekinumab als open-label intraveneuze inductiebehandeling gevolgd door gerandomiseerde dubbelblinde subcutane onderhoudsbehandeling met Ustekinumab bij pediatrische deelnemers met matig tot ernstig actieve ziekte van Crohn

Het doel van deze studie is het evalueren van de werkzaamheid van dosering van ustekinumab bij het induceren van klinische remissie (Global) en bij het handhaven van klinische remissie (VS); om het veiligheidsprofiel en de blootstelling aan ustekinumab (farmacokinetiek [PK]) te evalueren bij pediatrische deelnemers met matig tot ernstig actieve ziekte van Crohn.

Studie Overzicht

Toestand

Voltooid

Conditie

Studietype

Ingrijpend

Inschrijving (Werkelijk)

101

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Brussels, België, 1200
        • Cliniques Universitaires Saint Luc
      • Brussels, België, 1020
        • Universitair Kinderziekenhuis Koningin Fabiola
      • Ghent, België, 9000
        • UZ Gent
      • Jette, België, 1090
        • UZ Brussel
      • Leuven, België, 3000
        • UZ Leuven
      • Aachen, Duitsland, 52074
        • Universitätsklinikum Aachen
      • Berlin, Duitsland, 13353
        • Charite-Universitätsmedizin Berlin - Berlin
      • Essen, Duitsland, 45147
        • Universitätsklinikum Essen
      • Hanover, Duitsland, 30625
        • Medizinische Hochschule Hannover
      • Munich, Duitsland, 80337
        • Dr. von Haunersches Kinderspital
      • Regensburg, Duitsland, 93049
        • KUNO Klinik St. Hedwig
      • Ulm, Duitsland, 89075
        • Universitätsklinikum Ulm
      • Budapest, Hongarije, 1083
        • Semmelweis Egyetem
      • Debrecen, Hongarije, 4032
        • Debreceni Egyetem Klinikai Kozpont
      • Miskolc, Hongarije, 3526
        • Borsod Abauj Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktato Korhaz
      • Nyíregyháza, Hongarije, 4400
        • Szabolcs Szatmár Bereg Vármegyei Oktatókórház
      • Szeged, Hongarije, 6720
        • Szegedi Tudományegyetem, Gyermekgyógyászati Klinika és Gyermekegészségügyi Centrum
      • Be’er Ya‘aqov, Israël, 70300
        • Yitzhak Shamir Medical Center
      • Haifa, Israël, 34362
        • Carmel Medical Center
      • Jerusalem, Israël, 9103102
        • Shaare Zedek Medical Center
      • Petah Tikva, Israël, 4920235
        • Schneider Children's Medical Center
      • Bunkyō City, Japan, 113 8431
        • Juntendo University Hospital
      • Gunma, Japan, 371-0034
        • Gunma University Hospital
      • Ikoma, Japan, 630-0293
        • Kindai University Nara Hospital
      • Kurume, Japan, 830-0011
        • Kurume University Hospital
      • Saitama Shi, Japan, 330-8777
        • Saitama Childrens Medical Center
      • Sendai, Japan, 989-3126
        • Miyagi Children's Hospital
      • Setagaya Ku, Japan, 157 8535
        • National Center for Child Health and Development
      • Shimotsuke, Japan, 329-0498
        • Jichi Medical University Hospital
      • Tsu, Japan, 514 8507
        • Mie University Hospital
      • Gdansk, Polen, 80 803
        • Szpital im. M. Kopernika
      • Krakow, Polen, 30 663
        • Uniwersytecki Szpital Dzieciecy w Krakowie
      • Rzeszów, Polen, 35-302
        • Korczowski Bartosz Gabinet Lekarski
      • Warsaw, Polen, 04 501
        • WIP Warsaw IBD Point Profesor Kierkus
      • Warsaw, Polen, 04 730
        • Instytut Pomnik Centrum Zdrowia Dziecka
      • Kazan', Rusland, 420138
        • Kazan State Medical University
      • Moscow, Rusland, 119571
        • Russian National Research Medical University named after N.I.Pirogov
      • Nizhny Novgorod, Rusland, 603950
        • Privolzhsky Research Medical University of Ministry of Health of Russian Federation
      • Yaroslavl, Rusland, 150032
        • Yaroslavl Regional Children's Clinical Hospital
      • Birmingham, Verenigd Koninkrijk, B4 6NH
        • Birmingham Children's Hospital
      • Bristol, Verenigd Koninkrijk, BS2 8BJ
        • University Hospitals Bristol and Weston NHS Foundation Trust
      • Cambridge, Verenigd Koninkrijk, CB2 0QQ
        • Cambridge University Hospitals NHS Foundation Trust
      • Edinburgh, Verenigd Koninkrijk, EH16 4TJ
        • Royal Hospital for Children and Young People
      • London, Verenigd Koninkrijk, E1 2AT
        • Royal London Hospital
    • Delaware
      • Wilmington, Delaware, Verenigde Staten, 19803
        • Nemours DuPont Hospital for Children
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30342
        • Children's Center for Digestive Health Care
    • Minnesota
      • Rochester, Minnesota, Verenigde Staten, 55905
        • Mayo Clinic
    • New Jersey
      • Morristown, New Jersey, Verenigde Staten, 07962
        • Morristown Memorial Hospital
    • North Carolina
      • Charlotte, North Carolina, Verenigde Staten, 28207
        • Levine Childrens at Atrium Health
    • Ohio
      • Cleveland, Ohio, Verenigde Staten, 44106
        • University Hospitals Cleveland Medical Center
    • Pennsylvania
      • Hershey, Pennsylvania, Verenigde Staten, 17033
        • Penn State Hershey Children's Hospital
    • Texas
      • Fort Worth, Texas, Verenigde Staten, 76104
        • Cook Childrens Medical Center
    • Virginia
      • Fairfax, Virginia, Verenigde Staten, 22031
        • Pediatric Specialists Of Virginia

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

2 jaar tot 17 jaar (Kind)

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusiecriteria:

  • De ziekte van Crohn of de ziekte van Crohn met fistelvorming hebben met actieve colitis, ileitis of ileocolitis, op enig moment in het verleden bevestigd door endoscopie en histologie
  • Moet matig tot ernstig actieve ziekte van Crohn hebben (zoals gedefinieerd door een baseline Pediatric Crohn's Disease Activity Index [PCDAI]-score van meer dan [>] 30); ileocolonoscopie ondergaan met bewijs van actieve ziekte van Crohn, gedefinieerd als de aanwezigheid van ulceratie (wat gelijk is aan de Simple Endoscopic Score voor de ziekte van Crohn [SES-CD]-score groter dan of gelijk aan [>=] 3) tijdens screening voor dit onderzoek. De ileocolonoscopieprocedure moet plaatsvinden binnen ongeveer 3 weken voorafgaand aan de toediening van de onderzoeksinterventie in week 0 (inductieperiode). Een video-ileocolonoscopie die binnen 3 maanden voorafgaand aan het bezoek in week 0 (inductieperiode) is opgenomen, kan worden gebruikt in geval van herscreening van een deelnemer die een ileocolonoscopie heeft ondergaan maar om een ​​andere reden niet is geslaagd voor de eerste screening, van geval tot geval, na overleg met sponsor. Als ulceratie niet kan worden beoordeeld vanwege vernauwing of onvoldoende darmvoorbereiding, kan in plaats daarvan ten minste een van de volgende criteria worden toegepast: een abnormaal C-reactief proteïne (CRP) (> 0,3 milligram per deciliter [mg/dL] of 3,0 milligram per liter [mg/L] bij screening) of; fecaal calprotectine van >= 250 milligram per kilogram [mg/kg] of >= 250 microgram per gram [mcg/g] bij screening
  • Als u enterale voeding krijgt, moet u gedurende ten minste 2 weken voorafgaand aan inductieweek 0 (week I-0) een stabiel regime hebben gevolgd
  • Vrouwtjes in de vruchtbare leeftijd moeten een negatieve zeer gevoelige urine-zwangerschapstest hebben bij de screening en in week I-0 voorafgaand aan de toediening van de onderzoeksinterventie

Uitsluitingscriteria:

  • Heeft complicaties van de ziekte van Crohn, zoals symptomatische vernauwingen of stenose, syndroom van de korte darm, of enige andere manifestatie waarvan verwacht kan worden dat een operatie nodig is, die het gebruik van de PCDAI om de respons op therapie te beoordelen, zou kunnen verhinderen of mogelijk het vermogen om de effect van behandeling met ustekinumab
  • Een voorgeschiedenis hebben van latente of actieve granulomateuze infectie, histoplasmose of coccidioidomycose, of een niet-tuberculeuze mycobacteriële infectie hebben gehad voorafgaand aan screening
  • Aanwezigheid of geschiedenis van een maligniteit, inclusief aanwezigheid of geschiedenis van lymfoproliferatieve ziekte inclusief lymfoom, of tekenen en symptomen die wijzen op mogelijke lymfoproliferatieve ziekte, zoals lymfadenopathie van ongewone grootte of locatie (bijvoorbeeld knopen in de achterste driehoek van de nek, infraclaviculaire, epitrochleaire, of periaortale gebieden), en monoklonale gammopathie van onbepaalde betekenis, of klinisch significante hepatomegalie of splenomegalie
  • Een voorgeschiedenis hebben van matige of ernstige progressieve of ongecontroleerde lever- of nierinsufficiëntie; of significante cardiale, vasculaire, pulmonale, gastro-intestinale, endocriene, neurologische, hematologische, psychiatrische (inclusief suïcidaliteit) of metabole stoornissen
  • Een onderzoeksinterventie heeft gekregen inclusief eventuele onderzoeksvaccins of een invasief medisch hulpmiddel voor onderzoek heeft gebruikt binnen 3 maanden vóór de geplande eerste dosis van de onderzoeksinterventie of is momenteel ingeschreven in een onderzoeksstudie; ontvangst van een onderzoeksvaccin voor Coronavirus Disease 2019 (COVID-19) is geen automatisch uitsluitingscriterium

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Open-label Ustekinumab intraveneus (IV): inductieperiode
Alle deelnemers krijgen een enkele IV-toediening van ustekinumab in inductieweek 0 (I-0) op basis van lichaamsoppervlak (BSA) (milligram per vierkante meter [mg/m^2]) of op gewicht gebaseerde inductiedosis (milligram per kilogram [mg/kg]).
Ustekinumab wordt intraveneus toegediend tijdens de inductieperiode en subcutaan tijdens de onderhoudsperiode.
Experimenteel: Ustekinumab subcutaan (SC) elke 8 weken (q8w): onderhoudsperiode
Deelnemers krijgen subcutane toediening van ustekinumab q8w op basis van BSA (mg/m^2) of op gewicht gebaseerde inductiedosis (mg/kg) tijdens onderhoudsweken (week M)-0, M-8, M-16, M-24 , M 32 en M-40 en bijpassende placebo in week M-12 en M-36 om de blinden te behouden.
Ustekinumab wordt intraveneus toegediend tijdens de inductieperiode en subcutaan tijdens de onderhoudsperiode.
Bijpassende placebo zal worden toegediend als SC-injectie.
Experimenteel: Ustekinumab SC Elke 12 weken (q12w): onderhoudsperiode
Deelnemers krijgen subcutane toediening van ustekinumab q12w op basis van BSA (mg/m^2) of op gewicht gebaseerde inductiedosis (mg/kg) in week M-0, M-12, M-24, M-36 en overeenkomende placebo in week M-0, M-12, M-24, M-36 Weken M-8, M-16, M-32 en M-40 om de blinden te onderhouden.
Ustekinumab wordt intraveneus toegediend tijdens de inductieperiode en subcutaan tijdens de onderhoudsperiode.
Bijpassende placebo zal worden toegediend als SC-injectie.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 8 (Week I-8)
Tijdsspanne: Induction Week 8 (Week I-8)
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: hematocrit [HCT], erythrocyte sedimentation rate [ESR], Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations. The category of severity for each index item is assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score =5. For albumin level, the maximum score = 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Induction Week 8 (Week I-8)
US-specific Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44
Tijdsspanne: Maintenance Week 44 (Study Week 52)
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Tijdsspanne: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with TEAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. TEAEs were defined as AEs occurring at or after the initial administration of the study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
Tijdsspanne: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with TESAEs was reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly. TESAEs were defined as any SAE occurring at or after the initial administration of the study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With AEs Leading to Discontinuation of Study Intervention
Tijdsspanne: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
Number of participants with AEs leading to discontinuation of study intervention were reported.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
Global and US-specific Outcome Measures: Number of Participants With AEs of Special Interest (AESI)
Tijdsspanne: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. AESI were defined as any newly identified malignancy, or case of active TB, or opportunistic infection occurring after the first administration of study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology
Tijdsspanne: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with abnormalities in clinical laboratory parameters (hematology) were reported. It included hemoglobin (Hb). Grades 0-4 were based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), where Grade 0 was normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences. Higher grades showed more severe abnormalities. Only abnormalities where atleast one participant had data are reported. Inc = increased, Dec= decreased.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Chemistry
Tijdsspanne: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with abnormalities in clinical laboratory parameters were reported. It included chemistry measures: alanine aminotransferase (ALT), aspartate aminotransferase (AST),blood bilirubin (BB). Grades 0-4 were based on NCI-CTCAE version 5.0, where Grade 0 was Normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences. Higher grades showed more severe abnormalities. Only abnormalities where at least one participant had data are reported. Inc = increased, Dec= decreased.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Reactions Temporally Associated With Intravenous (IV) Infusion (Induction Period) and Subcutaneous (SC) Injection-Site Reactions (Maintenance Period)
Tijdsspanne: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with reactions temporally associated with intravenous (IV) infusion (Induction Period) and subcutaneous (SC) Injection-Site Reactions (Maintenance Period) were reported.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Serum Ustekinumab Concentrations
Tijdsspanne: Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44
Serum ustekinumab concentrations were reported.
Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 6 as Assessed by Short Pediatric Crohn's Disease Activity Index (sPCDAI)
Tijdsspanne: Induction Week 6 (Week I-6)
Clinical remission was defined as a short Pediatric Crohn's Disease Activity Index (sPCDAI) score <=10. The sPCDAI was composed of six components: abdominal pain, stool frequency, patient general well-being, body weight, abdominal examination (abdominal mass and tenderness), and extraintestinal manifestations. Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected clinical remission or minimal disease activity. Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90. Higher score indicate greater severity. The sPCDAI score was calculated only when >=3 of the 6 components were available.
Induction Week 6 (Week I-6)
Global Outcome Measure: Percentage of Participants With Clinical Response at Induction Week 8
Tijdsspanne: Induction Week 8
Assessment of response in children with Crohn's disease was evaluated using the PCDAI. Clinical response was defined as a reduction from baseline of >=12.5 points in the PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history (abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores (weight and height); physical examination scores (abdominal and perirectal disease); and extraintestinal manifestations. Each index item was assigned a severity score of 0 (normal), 5 (mild abnormality), or 10 (severe abnormality). For HCT and ESR, maximum score was 5, and for albumin level, maximum score was 10. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with a resulting score of <=30 on the 0-100 scale.
Induction Week 8
Global and US-specific Outcome Measures: Percentage of Participants With Clinical Response at Induction Week 6 as Assessed by sPCDAI
Tijdsspanne: Induction Week 6
sPCDAI clinical response was defined as reduction from baseline in the sPCDAI score of >=10. The 6-item sPCDAI score ranges from 0 (no disease activity) to 90 (severe disease activity),calculated by summing weighted scores for abdominal pain, stool frequency, general well-being, body weight, abdominal exam, and extraintestinal manifestations. Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected minimal disease activity. Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90. Higher score indicate greater severity. The sPCDAI score was only calculated when >=3 of the 6 components were available.
Induction Week 6
Global Outcome Measure: Percentage of Participants With Endoscopic Response at Maintenance Week 8 as Assessed by Simplified Endoscopic Score-Crohn's Disease (SES-CD)
Tijdsspanne: Maintenance Period Week 8 (Study Week 16)
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing. Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum. Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity. Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
Maintenance Period Week 8 (Study Week 16)
Global Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 8
Tijdsspanne: Maintenance Week 8 (Study Week 16)
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations. Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality). For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10. Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
Maintenance Week 8 (Study Week 16)
Global and US-specific Outcome Measures: Percentage of Participants With Endoscopic Response at Maintenance Week 44 as Assessed by SES-CD
Tijdsspanne: Maintenance Week 44 (Study Week 52)
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing. Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum. Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity. Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
Maintenance Week 44 (Study Week 52)
US-specific Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 44
Tijdsspanne: Maintenance Week 44 (Study Week 52)
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations. Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality). For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10. Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
Maintenance Week 44 (Study Week 52)
US-specific Outcome Measure: Percentage of Participants With Corticosteroid-free Clinical Remission at Maintenance Week 44
Tijdsspanne: Maintenance Period Week 44 (Study Week 52)
Corticosteroid-free remission was defined as PCDAI score of <=10 points and not receiving corticosteroids for at least 90 days prior to Week M-44. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Period Week 44 (Study Week 52)
Global Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44 Who Had Clinical Remission at Induction Week 8
Tijdsspanne: Maintenance Week 44 (Study Week 52)
Clinical remission was defined as Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Week 44 (Study Week 52)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

6 april 2021

Primaire voltooiing (Werkelijk)

28 november 2024

Studie voltooiing (Werkelijk)

3 maart 2025

Studieregistratiedata

Eerst ingediend

14 december 2020

Eerst ingediend dat voldeed aan de QC-criteria

14 december 2020

Eerst geplaatst (Werkelijk)

17 december 2020

Updates van studierecords

Laatste update geplaatst (Werkelijk)

30 juli 2026

Laatste update ingediend die voldeed aan QC-criteria

2 juli 2026

Laatst geverifieerd

1 juli 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Andere studie-ID-nummers

  • CR108864
  • 2019-004225-24 (EudraCT-nummer)
  • CNTO1275CRD3004 (Andere identificatie: Janssen Research & Development, LLC)
  • 2023-504978-38-00 (Register-ID: EUCT number)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Het beleid voor het delen van gegevens van de Janssen Pharmaceutical Companies of Johnson & Johnson is beschikbaar op www.janssen.com/clinical-trials/transparency. Zoals vermeld op deze site, kunnen verzoeken om toegang tot de onderzoeksgegevens worden ingediend via de Yale Open Data Access (YODA)-projectsite op yoda.yale.edu

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren